> ⚠️ Research Use Only: TB-500 (Thymosin Beta-4) is an investigational research peptide not approved by the FDA for human use. This article is for educational and research purposes only. All dosage parameters described here are reported from preclinical and research literature only. This content does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before considering any compound.
---
What Is TB-500 (Thymosin Beta-4)?
TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide encoded by the TMSB4X gene. The name "TB-500" refers to the specific fragment Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES — the bioactive region selected for research utility due to its stability and potent interaction with monomeric actin (G-actin).
Originally isolated from bovine thymus by Allan Goldstein and colleagues in the 1960s, Thymosin Beta-4 was subsequently found to be expressed in virtually every nucleated cell in the mammalian body — an unusually broad distribution that points to its fundamental role in cellular homeostasis. The LKKTET actin-binding motif is the molecular heart of the peptide's activity: it sequesters approximately 40–50% of the intracellular G-actin pool, keeping a reservoir available for rapid mobilization when cells need to migrate, proliferate, or repair damage.
For a comprehensive overview of TB-500's mechanism of action, biology, and preclinical research evidence, see our TB-500 Research Guide.
---
TB-500 vs BPC-157: Key Differences for Research
TB-500 and BPC-157 are frequently studied together as the "Wolverine Stack" in regenerative peptide research. While they share a focus on tissue repair, their mechanisms are distinct:
| Parameter | TB-500 | BPC-157 |
|---|---|---|
| Origin | Synthetic analog of endogenous Thymosin Beta-4 | Synthetic analog of gastric pentadecapeptide |
| Primary mechanism | G-actin sequestration → cell motility, angiogenesis | Nitric oxide pathway → vascular repair |
| Key strength in research | Systemic, long-range healing; cardiac repair; stem cell activation | Local wound/tendon healing; gastrointestinal protection |
| Receptor target | Indirect via actin cytoskeleton; PI3K/Akt pathway | Growth hormone receptor; nitric oxide synthase |
| Research dose range (preclinical) | 150–600 mcg/kg in rodent studies | 100–200 mcg/kg in rodent models |
| Typical vial size | 5 mg lyophilized powder | 5 mg lyophilized powder |
These distinctions explain why researchers studying musculoskeletal repair, cardiac recovery, or systemic inflammation often use both compounds in parallel — they act on complementary pathways rather than competing ones. See the BPC-157 vs TB-500 comparison for a deeper mechanistic analysis.
---
Key Research Studies on TB-500
Wound Healing Literature
The wound healing research base for Thymosin Beta-4 is among the most mature for any research peptide. Foundational work from Malinda and Goldstein demonstrated that Thymosin Beta-4 stimulates directional migration of human umbilical vein endothelial cells, with the LKKTET actin-binding motif implicated in this activity (Malinda KM, Goldstein AL, et al. FASEB Journal, 1997; PMID 9194528).
A Phase II randomized controlled clinical trial (NCT00832091) investigated Thymosin Beta-4 in patients with chronic venous stasis ulcers. Treatment-arm patients demonstrated statistically significant acceleration in wound closure rate, with histological analysis confirming more organized collagen matrix architecture in treated wounds compared to controls.
Cardiac Repair Research
Smart and colleagues published landmark research in Nature demonstrating that Thymosin Beta-4 induces adult epicardial progenitor mobilization and neovascularization, priming epicardial cells to reactivate embryonic gene programs (Wilms' tumor 1/WT1 expression), migrate into infarcted myocardium, and differentiate into functional cardiomyocytes (Smart N, Risebro CA, et al. Nature, 2007; PMID 17108969) — a landmark finding for cardiac regeneration research.
Musculoskeletal and Tendon Repair
Rodent models of tendon injury have reported improved load-to-failure and more organized collagen fiber alignment in Thymosin Beta-4-treated animals versus controls, consistent with the peptide's actin-mediated effects on fibroblast migration and matrix remodeling (mechanism established in Malinda & Goldstein, 1997; PMID 9194528).
Tendon and musculoskeletal research represents one of the primary applications explored in the TB-500 literature, with rodent rotator cuff, ligament, and skeletal muscle injury models all showing consistent pro-repair effects across multiple independent research groups.
Neurological Research
Emerging preclinical literature has explored TB-500 in neurological injury models, hypothesizing effects on lesion volume and functional recovery via anti-apoptotic signaling and oligodendrocyte-mediated myelin repair. This application area is less mature than the wound-healing and cardiac literature and specific claims here should be treated as preliminary pending a dedicated citation review.
---
Reconstitution Protocol for Research Use
TB-500 is commercially available as a lyophilized (freeze-dried) powder, typically supplied in 2 mg or 5 mg vials. Proper reconstitution is essential for maintaining peptide integrity and ensuring accurate dosing in research applications.
Materials Required
- •Bacteriostatic water (BW): The standard diluent for TB-500 in research. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable life of the reconstituted solution to approximately 14–28 days when refrigerated. Sterile water for injection (SWFI) is an acceptable alternative but should be used within 24–48 hours.
- •Insulin syringes: 1 mL, 27–31G needles for precise volumetric measurement
- •Alcohol swabs: For vial septum sterilization before any needle insertion
- •Cold storage: 2–8°C refrigerator for reconstituted solution
Step-by-Step Reconstitution
1. Allow vials to reach room temperature before opening to prevent condensation on the powder
2. Wipe the vial septum with an alcohol swab and allow to dry (30 seconds)
3. Prepare your bacteriostatic water volume. For a 5 mg vial, adding 2.5 mL of BW produces a concentration of 2 mg/mL (2,000 mcg/mL). Adding 1 mL produces 5 mg/mL. Choose a concentration that minimizes measurement error for your target research dose.
4. Inject the bacteriostatic water slowly against the inner wall of the vial — do NOT aim the stream directly at the lyophilized cake, as forceful streams can denature the peptide through mechanical shear
5. Gently swirl the vial (do not vortex or shake aggressively) until the powder is fully dissolved. The solution should be clear and colorless.
6. Inspect for particulates — any cloudiness, visible floaters, or discoloration indicates degradation and the vial should not be used
Standard Dilution Reference Table
| BW Added to 5 mg Vial | Concentration | Volume per 1 mg | Volume per 500 mcg |
|---|---|---|---|
| 1.0 mL | 5,000 mcg/mL | 0.20 mL (20 units) | 0.10 mL (10 units) |
| 2.5 mL | 2,000 mcg/mL | 0.50 mL (50 units) | 0.25 mL (25 units) |
| 5.0 mL | 1,000 mcg/mL | 1.00 mL (100 units) | 0.50 mL (50 units) |
Units refer to markings on a standard U-100 insulin syringe.
Storage After Reconstitution
- •Refrigerated (2–8°C): 14–28 days when reconstituted with bacteriostatic water
- •Frozen (-20°C): Reconstituted TB-500 can be frozen in single-use aliquots; repeated freeze-thaw cycles degrade peptide integrity and should be minimized (one freeze-thaw maximum is the standard research practice guideline)
- •Lyophilized (unreconstituted) at -20°C: 24+ months when stored properly, protected from light and moisture
---
Dosage Parameters in Research Literature
⚠️ The following parameters are reported from preclinical animal studies and limited human research literature only. They are not recommendations for human use and should not be applied outside a formal, approved research context.
Animal Study Parameters
TB-500 dosing in rodent research models has varied substantially across studies depending on the indication, route of administration, and species:
| Research Application | Rodent Study Range | Administration Route | Study Type |
|---|---|---|---|
| Wound healing | 150–300 mcg/kg | Subcutaneous or intraperitoneal | Rat/mouse wound models |
| Cardiac repair | 150–600 mcg/kg | Intraperitoneal or intravenous | Mouse MI models |
| Tendon/musculoskeletal repair | 150–500 mcg/kg | Subcutaneous near injury | Rat Achilles tendon models |
| Neurological recovery | 200–400 mcg/kg | Intraperitoneal | Mouse TBI models |
Translating these rodent doses to other species requires species-specific pharmacokinetic data and body surface area normalization — this is outside the scope of an educational research overview.
Phase II Clinical Trial Dosing
The only published human clinical trial using Thymosin Beta-4 (NCT00832091) employed topical formulations (0.03–0.3% w/w) applied directly to chronic venous stasis ulcer wound surfaces, rather than systemic injection. This trial's design and dosing approach differs substantially from the systemic research protocols used in animal studies and does not provide a basis for systemic dose translation.
Loading vs. Maintenance Protocols in Published Literature
Some published research protocols use biphasic dosing designs — a higher-frequency initial "loading" phase followed by a reduced-frequency "maintenance" phase. This approach is mechanistically plausible given TB-500's known role in tissue remodeling timelines: angiogenesis and collagen matrix reorganization require sustained signaling over weeks, while acute cell migration effects may require higher initial concentrations to establish the response.
However, head-to-head comparisons of loading versus continuous fixed-dose protocols have not been published in peer-reviewed literature for TB-500 specifically. The biphasic model appears most frequently in research design discussions and gray literature rather than controlled experimental comparisons.
---
Injection Sites in Research Context
In preclinical research with animal models, TB-500 has been administered via several routes:
- •Subcutaneous (SubQ): Most common route in published rodent studies. Absorption is gradual, with peak plasma levels typically within 30–60 minutes. Rotating injection sites across body regions is standard practice in animal research protocols.
- •Intraperitoneal (IP): Common in mouse studies for faster systemic absorption. Used primarily in animal research settings where IP access is standardized.
- •Intravenous (IV): Used in some cardiac studies requiring immediate systemic delivery. Requires sterile technique, appropriate training, and formal research protocols.
- •Topical: Used in wound healing surface application studies, particularly the clinical trial referenced above.
The subcutaneous route dominates in published animal research due to its practical reproducibility and consistent pharmacokinetic profile.
---
TB-500 + BPC-157 Stack in Research: The "Wolverine Stack"
The combination of TB-500 and BPC-157 has attracted significant interest in the research community due to the complementary and mechanistically non-overlapping nature of their effects:
TB-500's primary mechanisms:
- •G-actin sequestration promoting systemic cell motility
- •VEGF-mediated angiogenesis and new vessel formation
- •PI3K/Akt anti-apoptotic signaling protecting vulnerable cells
- •Stem cell mobilization and epicardial progenitor activation
BPC-157's primary mechanisms:
- •Nitric oxide synthase (NOS) upregulation promoting vasodilation and vascular repair
- •Growth hormone receptor modulation
- •Gastrointestinal mucosal protection via COX-2 inhibition
- •Local wound closure through fibroblast activation
These pathways converge on tissue repair outcomes but operate through distinct receptors and signaling cascades, making simultaneous administration mechanistically non-redundant. No peer-reviewed studies have specifically evaluated the co-administration of synthetic TB-500 with synthetic BPC-157 in controlled animal models — the synergy hypothesis is mechanistically reasonable but remains formally unvalidated.
For BPC-157 dosage parameters and reconstitution protocols, see the BPC-157 Dosage Research Protocol Guide. For a combined dosing schedule covering both compounds, see the BPC-157 + TB-500 Stack Protocol Guide. For a combined administration protocol, see the BPC-157 + TB-500 Stack Protocol Guide.
---
Where to Find TB-500 for Research
Peptides.SO aggregates TB-500 listings from 60+ research peptide suppliers, with real-time pricing, purity documentation, and third-party testing data. Compare current options at /peptide/tb-500.
Key supplier selection criteria for research applications:
- •Certificate of Analysis (COA): Third-party HPLC purity testing at ≥99% is the standard benchmark for research-grade peptides
- •Mass spectrometry confirmation: Validates the correct molecular weight (~4,963 Da) and amino acid sequence
- •Lyophilization quality: Properly lyophilized powder appears as a white, airy cake — not compressed, yellowed, or discolored
Use the peptide comparison tool to filter by purity, vial size, and price across available suppliers. For volume and concentration math during reconstitution, use the peptide reconstitution calculator.
---
Frequently Asked Questions
Q: Is TB-500 the same as Thymosin Beta-4?
TB-500 is a synthetic research analog comprising a specific fragment of the Thymosin Beta-4 protein. The terms are often used interchangeably in research circles, but they are technically distinct: Thymosin Beta-4 is the full 43-amino-acid endogenous protein, while TB-500 refers to the synthetic Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES fragment. Both share the key LKKTET actin-binding domain that mediates the majority of the peptide's bioactivity.
Q: How does TB-500's storage stability compare to BPC-157?
Both peptides are supplied as lyophilized powders with comparable storage requirements. TB-500's reconstituted solution shelf life (14–28 days refrigerated with bacteriostatic water) is similar to BPC-157's. The lyophilized powder for both compounds is stable for 24+ months at -20°C when stored away from light and moisture.
Q: Does TB-500 require refrigeration before reconstitution?
Unreconstituted lyophilized TB-500 powder should be stored at -20°C for maximum shelf life. Some suppliers specify short-term room temperature stability (1–2 months), but long-term room temperature storage degrades peptide integrity. Once reconstituted, refrigeration at 2–8°C is required.
Q: What is the molecular weight of TB-500 and why does it matter?
TB-500 has a molecular weight of approximately 4,963 Da. This is relevant for research design because it affects subcutaneous absorption kinetics (larger peptides absorb more slowly than small molecules), it means the compound must be administered by injection rather than orally (peptides of this size are substantially degraded by gastrointestinal proteases before reaching systemic circulation), and it informs mass spectrometry verification of peptide identity.
Q: Why is bacteriostatic water recommended over regular sterile water?
Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, preventing bacterial contamination and extending the reconstituted peptide solution's usable life from 24–48 hours (sterile water) to 14–28 days. For research applications where multiple doses are drawn from a single vial over time, this extended stability window is practically significant.
Q: Is TB-500 detectable in anti-doping tests?
Yes. The World Anti-Doping Agency (WADA) includes Thymosin Beta-4 and its synthetic analogs (including TB-500) on the Prohibited List under peptide hormones, growth factors, related substances, and mimetics. This regulatory classification is part of the broader research context for this compound.
---
Summary
TB-500 (Thymosin Beta-4) occupies a central position in preclinical regenerative research due to its systemic, multi-modal mechanism of action — actin cytoskeletal regulation, angiogenesis promotion, anti-inflammatory signaling, and stem cell mobilization acting in concert rather than through a single pathway. The wound healing, cardiac repair, tendon, and neurological preclinical literature is substantive and methodologically sound, with some transition into Phase II human research for specific wound indications.
For research applications, proper reconstitution with bacteriostatic water, cold storage, and careful volumetric dosing are the primary practical considerations. Its complementarity with BPC-157's mechanisms — particularly their non-overlapping receptor targets and pathway engagement — makes the combination a frequent subject of research interest.
TB-500 is not approved by the FDA or any major regulatory agency for therapeutic use in humans. All use outside formally approved research protocols is outside the scope of this article.
---
> Full Research Use Only Disclaimer: TB-500 (Thymosin Beta-4) and all related compounds discussed in this article are for in vitro and in vivo research purposes only. They are not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other regulatory authority for use as therapeutic agents in humans. The dosage parameters, protocols, and research applications described here are derived from peer-reviewed preclinical literature and limited Phase II clinical trial data. Nothing in this article constitutes medical advice, and no information presented should be interpreted as a recommendation for human self-administration. Peptides.SO is a research information and price comparison platform. Use of any research compound outside of a formally regulated research or clinical setting may violate applicable laws and regulations.